Ortin Global Quarterly Results for Trading Insights
In Mar 2012, Ortin Global (ORTINGLOBE) reported revenue ₹18 Cr and net profit ₹-2 Cr. For annual financials, live price and key ratios, visit ORTINGLOBE share price screener.
ORTINGLOBE Quarterly Results — Revenue, Profit & EPS Highlights
Ortin Global latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore ORTINGLOBE share price history to track price trends across different timeframes.
- Revenue of ₹18 Cr in Mar 2012 (+38.5% vs Jun 2012)
- Net Profit of ₹-2 Cr in Mar 2012
- EBITDA of ₹-3 Cr in Mar 2012 (-200.0% vs Jun 2012)
- Operating Margin of -19.0% in Mar 2012 (-14.0pp vs Jun 2012)
- Earnings Per Share of ₹-1.13 in Mar 2012 (-534.6% vs Jun 2012)
Ortin Global Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ORTINGLOBE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2012 | Jun 2012 | QoQ | YoY |
|---|---|---|---|---|
| Revenue (₹ Cr) | 18 | 13 | 38.5% | - |
| Net Profit (₹ Cr) | -2 | 0 | - | - |
| EBITDA (₹ Cr) | -3 | -1 | - | - |
| EPS (₹) | -1.13 | 0.26 | - | - |
| Operating Margin (%) | -19.0% | -5.0% | - | - |
ORTINGLOBE Share Price Trend — 1-Year Movement Across Quarterly Results
Ortin Global 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with ORTINGLOBE stock valuation models to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ORTINGLOBE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Ortin Global latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores